Market Cap (In USD)
1.37 Billion
Revenue (In USD)
12.76 Million
Net Income (In USD)
-176.93 Million
Avg. Volume
3101.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.6-16.75
- PE
- -
- EPS
- -
- Beta Value
- -0.001
- ISIN
- NL00150012K9
- CUSIP
- -
- CIK
- 1936258
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Michael Harvey Davidson FACC, Facp., M.D.
- Employee Count
- -
- Website
- https://www.newamsterdampharma.com
- Ipo Date
- 2021-02-10
- Details
- NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
More Stocks
-
ANSINDUSANS Industries Limited
ANSINDUS
-
IBG
-
TKCOFToho Co., Ltd.
TKCOF
-
SURSurteco Group SE
SUR
-
ELEKElektros Inc.
ELEK
-
SYNEX-R
-
ITNSItonis, Inc.
ITNS
-
TEAMG